The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy.
10.4048/jbc.2012.15.2.189
- Author:
Jung Sun LEE
1
;
Byung Ho SON
;
Sei Hyun AHN
Author Information
1. Department of Surgery, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
HER2/neu;
Trastuzumab
- MeSH:
Antibodies, Monoclonal, Humanized;
Breast Neoplasms;
Carcinoma, Ductal;
Humans;
Immunoassay;
In Situ Hybridization, Fluorescence;
Luminescence;
Neoadjuvant Therapy;
Neoplasm, Residual;
Polymerase Chain Reaction;
Trastuzumab
- From:Journal of Breast Cancer
2012;15(2):189-196
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Little information exists about the possible influence of serum HER2/neu on response to chemotherapy. We propose that the assessment of serum HER2/neu in a pretreatment serum sample may be useful in predicting response to neoadjuvant chemotherapy. METHODS: All breast cancer patients were tested by immunohistochemical stain and fluorescent in situ hybridization for HER2/neu before treatment. Serum HER2/neu was twice measured by chemiluminescence immunoassay (ADVIA Centaur System) before neoadjuvant chemotherapy and before operation. The cut-off value was 10.2 mg/mL, according to the previous study. Pathologic complete response (pCR) was considered as no residual tumor or remnant ductal carcinoma in situ; partial response (PR) was a less than 50% decrease in maximal diameter in pathologic tumor size. The measurements for the changes of serum HER2/neu were defined as pretreatment HER2/neu-preoperation HER2/neu. We compared the change of serum HER2/neu between that from before chemotherapy and that after chemotherapy, the pathologic complete response and partial response, and the trastuzumab group and anthracycline group. RESULTS: Serum HER2/neu was decreased after neoadjuvant chemotherapy. The mean of serum HER2/neu in prechemotherapy was 15.4+/-9.0 ng/mL, and that of postchemotherapy was 10.5+/-2.0 ng/mL (p=0.04). Pathologic response was correlated with the change of serum HER2/neu (PR, 11.7+/-2.2 ng/mL vs. pCR, 23.7+/-13.1 ng/mL; p=0.01). In the trastuzumab group, pCR was marginally correlated with the change of serum HER2/neu (PR, 0.8+/-0.84 ng/mL vs. pCR, 21.1+/-13.2 ng/mL; p=0.08). CONCLUSION: Serum HER2/neu levels during treatment were associated with pathologic response in patients receiving neoadjuvant chemotherapy, particularly, in a trastuzumab-based regimen. The change of serum HER2/neu levels may serve in monitoring neoadjuvant therapy in HER2/neu-overexpressed breast cancer.
